 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript...

Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript

Conference call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023WOBURN, MA / ACCESSWIRE / November 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company...

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

WOBURN, MA / ACCESSWIRE / November 3, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report...

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

WOBURN, MA / ACCESSWIRE / October 31, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ('Biofrontera' or the 'Company'), a biopharmaceutical company specializing in the commercialization of dermatologic...

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

Patent Application Filed with Potential to Extend Ameluz Protection to 2043WOBURN, MA / ACCESSWIRE / October 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ('Biofrontera' or the 'Company'), a...

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

WOBURN, MA / ACCESSWIRE / October 5, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ('Biofrontera' or the 'Company'), a biopharmaceutical company specializing in the commercialization of dermatologic...

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Biofrontera AG sees Q3 revenue $8.7M-$9M, two est $7.03M

Revenues Increased 101% to 108% Over the Prior-Year QuarterAffirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022WOBURN, MA / ACCESSWIRE / October 4, 2023 / Biofrontera Inc...

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ('Biofrontera' or the 'Company'), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe...

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

Biofrontera (NASDAQ:BFRI  Get Free Report) and Harmony Biosciences (NASDAQ:HRMY  Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, ...

Biofrontera (NASDAQ:BFRI) & Harmony Biosciences (NASDAQ:HRMY) Head-To-Head Review

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Watchers	8,591
52-Wk Low	$2.73
52-Wk High	$22.39

Market Cap	$5.69M
Volume (M)	13,170.00
52-Wk High	$22.39
52-Wk Low	$2.73

BFRI Biofrontera Inc

About

Feed

News

Earnings

Fundamentals